OBJECTIVE: To investigate if treatment response predicts continuation of anti-tumor necrosis factor (TNF) treatment in patients with rheumatoid arthritis (RA). METHODS: We investigated if treatment response and/or achieving a certain activity state at 6 weeks or 3 months predicts continuation of treatment in an observational cohort of 1789 anti-TNF-naive patients with established RA disease from southern Sweden. RESULTS: Response to treatment at 6 weeks at overall/American College of Rheumatology (ACR20) or good/major level (except ACR70) significantly predicted drug continuation. Response according to all criteria sets at overall/ACR20 and at good/major/ACR70 level predicted drug continuation at 3 months, as did achieving low disease activity at 3 months irrespective of activity index applied. Remaining in a high disease activity state predicted drug discontinuation at both timepoints and according to all criteria sets. CONCLUSION: Response criteria may be useful aids in deciding on continuation of TNF blockade in RA as early as after 6 weeks of treatment. The various criteria sets perform similarly.
OBJECTIVE: To investigate if treatment response predicts continuation of anti-tumor necrosis factor (TNF) treatment in patients with rheumatoid arthritis (RA). METHODS: We investigated if treatment response and/or achieving a certain activity state at 6 weeks or 3 months predicts continuation of treatment in an observational cohort of 1789 anti-TNF-naive patients with established RA disease from southern Sweden. RESULTS: Response to treatment at 6 weeks at overall/American College of Rheumatology (ACR20) or good/major level (except ACR70) significantly predicted drug continuation. Response according to all criteria sets at overall/ACR20 and at good/major/ACR70 level predicted drug continuation at 3 months, as did achieving low disease activity at 3 months irrespective of activity index applied. Remaining in a high disease activity state predicted drug discontinuation at both timepoints and according to all criteria sets. CONCLUSION: Response criteria may be useful aids in deciding on continuation of TNF blockade in RA as early as after 6 weeks of treatment. The various criteria sets perform similarly.
Authors: Jeffrey R Curtis; Shuo Yang; Lang Chen; Grace S Park; Bojena Bitman; Brian Wang; Iris Navarro-Millan; Arthur Kavanaugh Journal: Ann Rheum Dis Date: 2011-10-13 Impact factor: 19.103
Authors: Jeffrey R Curtis; Theresa McVie; Ted R Mikuls; Richard J Reynolds; Iris Navarro-Millán; James O'Dell; Larry W Moreland; S Louis Bridges; Veena K Ranganath; Stacey S Cofield Journal: J Rheumatol Date: 2013-04-15 Impact factor: 4.666
Authors: Bart J F van den Bemt; Alfons A den Broeder; Gert-Jan Wolbink; Aatke van den Maas; Yechiel A Hekster; Piet L C M van Riel; H Bart Benraad; Frank H J van den Hoogen Journal: Br J Clin Pharmacol Date: 2013-12 Impact factor: 4.335
Authors: Young Mo Kang; Young-Eun Park; Won Park; Jung-Yoon Choe; Chul-Soo Cho; Seung-Cheol Shim; Sang Cheol Bae; Chang-Hee Suh; Hoon-Suk Cha; Eun Mi Koh; Yeong-Wook Song; Bin Yoo; Shin-Seok Lee; Min-Chan Park; Sang-Heon Lee; Catherine Arendt; Willem Koetse; Soo-Kon Lee Journal: Korean J Intern Med Date: 2018-01-05 Impact factor: 2.884